Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

9,053 public trials 1,837 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing GoBroad Hospital Beijing, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, China
  • Shanghai Liquan Hospital Shanghai, China
View Trial Details
Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations
  • Rigshospitalet ( Site 0802) Copenhagen, Capital Region, Denmark
  • Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804) Aarhus Nord, Central Jutland, Denmark
  • Odense Universitetshospital ( Site 0801) Odense, Region Syddanmark, Denmark
  • Rambam Health Care Campus ( Site 0903) Haifa, Israel
View all 21 locations
View Trial Details
Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662

Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +20 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
View all 114 locations
View Trial Details
Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Infirmary Cancer Care ( Site 0157) Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona, United States
  • Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona, United States
  • City of Hope - Phoenix ( Site 0202) Goodyear, Arizona, United States
View all 144 locations
View Trial Details
Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Colorado Blood Cancer Institute ( Site 7000) Denver, Colorado, United States
  • SCRI Oncology Partners ( Site 0100) Nashville, Tennessee, United States
  • Instituto Alexander Fleming ( Site 1404) Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) Rosario, Santa Fe Province, Argentina
View all 39 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 272 locations
View Trial Details
Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

NCT03739814

Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, DNA Virus Infections, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 280 locations
View Trial Details
Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Hemic and Lymphatic Diseases, +10 more
Locations
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Highlands Oncology Group Fayetteville, Arkansas, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
View all 67 locations
View Trial Details

Related conditions